Impact of the PCSK9 Inhibitor Evolocumab on the Pharmacodynamic Effects of Clopidogrel in Patients With Atherosclerotic Cardiovascular Disease and High On-Treatment Platelet Reactivity
Phase of Trial: Phase IV
Latest Information Update: 04 Oct 2017
At a glance
- Drugs Evolocumab (Primary)
- Indications Atherosclerosis; Cardiovascular disorders
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 27 Sep 2017 Status changed from not yet recruiting to recruiting.
- 14 Sep 2017 Planned initiation date changed from 1 Aug 2017 to 18 Sep 2017.